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A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1):
relationship ofa homozygous mutation at position 609 ofthe NQO1 cDNA
to NQO1 activity
Sir - NQO1 has attracted considerable attention owing to its
ability to deactivate a broad range of xenobiotics while
activating certain anti-tumour quinones (Ross et al., 1994). A
number of recent reports have highlighted the occurrence and
potential significance of a point mutation in the NQO1 gene
which is associated with a loss of NQO1 activity in both
normal and tumour tissue (Traver et al., 1992; Eickelmann et
al., 1994a,b; Rosvold et al., 1995; Kolesar et al., 1995). The
mutation is a C to T point mutation at position 609 of the
NQO1 cDNA which codes for a proline to serine substitution
in the amino acid sequence of the protein (Traver et al.,
1992). The mutation was originally characterised in the BE
human colon adenocarcinoma cell line by SSCP analysis and
sequencing (Traver et al., 1992) and subsequently in the H596
human non-small-cell lung cancer cell line by a polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) technique (Traver et al., 1995). Both the BE
and H596 cell lines had moderate NQO1 mRNA expression
but extremely low or non-detectable NQO1 activity. Purified,
recombinant BE and H596 mutant NQO1 proteins expressed
in E. coli have residual activity (< 10% of wild-type). While
both BE and H596 recombinant mutant proteins reacted with
a mouse monoclonal antibody raised against human NQO1,
immunoblot analysis of BE and H596 cell lines did not detect
NQO1 protein expression (Siegel et al., 1995). This suggests
that in cells the mutant protein may not be made or that the
mutant protein may be made but rapidly degraded. Kuehl et
al. (1995) have recently examined the relationship between
the heterozygous mutation at position 609 and NQO1
activity. These data demonstrate a wide range of NQO1
activity in IC to T heterozygotes and suggests a significant
role for post-transcriptional modification in determination of
NQO1 activity.
In the paper by Kuehl et al. (1995), the BE cell line is
described as heterozygous for the 9C-T point mutation
with very low NQO1 activity. An additional fibroblastoid cell
line, the 3701T line, was reported as homozygous for the
mutation with very low NQO1 activity. Since these results
differed, with respect to the BE cell line, from the original
report of Traver et al. (1992), the two laboratories involved
have exchanged stocks of BE cells and repeated the Hinfl
PCR-RFLP assay for the mutation at position 609
(Eickelmann et al., 1994b). Both stocks of BE cells have
consistently been found to be homozygous for the 609 point
mutation. The reasons for the appearance of the BE cells as
heterozygous for the mutation in the report of Kuehl et al.
(1995) are unclear. In addition, both the BE cells and the
3701T cells were found to have no detectable NQO1 protein
by immunoblot analysis (employing a human monoclonal
antibody to NQO1) and extremely low or non-detectable
NQO1 activity using standard activity assays [dicoumarol
inhibition of dichlorophenolindophenol (DCPIP) reduction].
The NQO1 activity of 9C-T homozygous mutants, such as
BE and 3401T cells, has been reported as either non-
detectable or as extremely low (Siegel et al., 1992; Traver et
al., 1992; Kuehl et al., 1995). Because of the somewhat non-
specific nature of both DCPIP as a substrate and dicoumarol
as an inhibitor (Ross et al., 1993), it is possible that the
extremely low rates of dicoumarol-inhibitable DCPIP
reduction obtained in BE, H596 or 3701T cells may reflect
the presence of reductases other than NQO1. Our joint
findings confirm previous results that the BE cells are
homozygous for the 609C-T mutation and that the presence
of the homozygous mutation is associated with a loss of
NQO1 protein activity (Traver et al., 1992, 1995). The same
conclusion was reached by Eickelmann et al. (1994) who
reported that a cell line and three human kidney carcinoma
samples without detectable NQO1 activity were all homo-
zygous for the IC to T mutation.
An alternatively spliced form of NQO1 lacking exon 4
and the quinone binding site has recently been reported
(Gasdaska et al., 1995). This form of NQO1 has minimal
enzyme activity with traditional model substrates for NQO1
but retains immunoreactivity and can be detected using a
polyclonal antibody to NQO1 (Gasdaska et al., 1995). We
have also examined BE and H596 cells for NQO1 protein
using the same polyclonal antibody used by Gasdaska and
colleagues and were unable to detect NQO1 protein. We
have recently suggested a different form of alternate splicing
as a possible explanation for the appearance of marked
NQO1 activity in a fibroblastoid cell line, G38-8X, in the
absence of detectable protein by immunoblot analysis
(Kuehl et al., 1996). We reasoned that an alternatively
spliced form of NQO1 might retain catalytic activity but
have lost the epitope required for immunoreactivity with the
antibody against NQO1 (Kuehl et al., 1996). This would not
be a plausible explanation for the lack of NQO1 protein in
homozygous 609C to T mutants since these cells are
essentially devoid of both NQO1 immunoreactivity and
NQO1 activity.
In conclusion, although a heterozygous C to T mutation at
position 609 of the NQO1 cDNA may be associated with
widely differing NQOl activities, the presence of a
homozygous C-T mutation at position 609 results in a loss
of NQO1 protein and activity. The homozygous mutation
represents a polymorphism in NQO1 which may be of
significance since its prevalence in various populations has
been reported to be between 6% and 17% (Rosvold et al.,
1995; Kuehl et al., 1995; Eickelmann et al., 1994a; Traver et
al., 1996). The role of this polymorphism with respect to
impaired protection from xenobiotic toxicity is under
investigation (Rothman et al., 1996).
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